Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DOXIL (LIPOSOMAL) vs VYXEOS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Doxorubicin intercalates between DNA base pairs, inhibits topoisomerase II, and generates free radicals, leading to DNA damage and cell death. Liposomal encapsulation prolongs circulation time and alters biodistribution.
Daunorubicin and cytarabine are both antineoplastic agents. Daunorubicin intercalates with DNA, inhibits topoisomerase II, and generates free radicals leading to DNA damage and cell death. Cytarabine is a nucleoside analog that inhibits DNA polymerase by competing with cytidine triphosphate, incorporating into DNA and RNA, and causing chain termination.
Ovarian cancer after failure of platinum-based chemotherapy,AIDS-related Kaposi sarcoma,Multiple myeloma in combination with bortezomib
FDA: Treatment of newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients aged 1 year and older.
Doxorubicin HCl liposome injection 20 mg/m2 intravenously over 1 hour every 4 weeks.
Each unit contains 44 mg daunorubicin and 100 mg cytarabine. Adults: 1 unit/m² IV over 90 minutes on days 1, 3, and 5 for induction; up to 2 cycles. For consolidation: 1 unit/m² IV over 90 minutes on days 1 and 3; up to 2 cycles.
Terminal half-life is approximately 30–40 hours, prolonging drug exposure and allowing every-4-week dosing.
Daunorubicin: terminal half-life approximately 56 h; cytarabine: terminal half-life approximately 31 h. The prolonged half-lives reflect sustained release from liposomes, allowing continuous exposure.
Primarily hepatically metabolized by aldo-keto reductases to doxorubicinol (active metabolite); also metabolized by cytochrome P450 (minor) and glycosidases.
Daunorubicin is metabolized via aldo-keto reductases to daunorubicinol, which is active. Cytarabine is primarily metabolized by cytidine deaminase to inactive uracil arabinoside (ara-U).
Primarily hepatic metabolism and biliary excretion; urinary excretion accounts for <10% of the administered dose as unchanged drug.
Primarily hepatobiliary excretion; 70-80% of dose recovered in feces as metabolites, less than 10% in urine as unchanged liposomal daunorubicin and cytarabine.
Approximately 90% bound to plasma proteins, primarily albumin.
Daunorubicin: approximately 60-70% bound to albumin and tissue proteins; cytarabine: approximately 15% bound to albumin.
Vd approximately 2.8 L/m² (not directly L/kg; low Vd indicates predominant plasma compartment retention).
Daunorubicin: Vd approximately 0.5-1 L/kg, indicating extensive tissue distribution; cytarabine: Vd approximately 0.3-0.5 L/kg, distributed mainly in total body water.
Only intravenous administration; oral bioavailability is negligible.
Not applicable (IV only); oral bioavailability not established for liposomal formulation.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended in severe renal impairment (Cr Cl <30 m L/min) due to lack of data.
Contraindicated in severe renal impairment (Cr Cl < 30 m L/min). For Cr Cl 30-60 m L/min: reduce dose by 25%. Monitor renal function.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: not recommended.
Contraindicated in severe hepatic impairment (Child-Pugh C). For Child-Pugh B: reduce dose by 50%. For Child-Pugh A: no adjustment needed.
Safety and efficacy not established in pediatric patients.
Safety and efficacy not established. No standard pediatric dosing. Use only in clinical trials.
No specific dose adjustment recommended, but monitor for increased toxicity (e.g., cardiotoxicity, myelosuppression) due to age-related organ function decline.
No specific dose adjustment based on age alone. Monitor renal and hepatic function; consider dose reduction in frail elderly patients due to increased toxicity risk.
Cardiotoxicity: risk of myocardial damage, including acute left ventricular failure. Myelosuppression: severe, dose-limiting. Hepatic impairment: requires dose reduction. Infusion reactions: may be severe or life-threatening. Must be administered by physician experienced in cancer chemotherapy.
WARNING: DAUNORUBICIN IS A CARDIOTOXIC AGENT. DAUNORUBICIN CAN CAUSE MYELOSUPPRESSION AND SEVERE BLEEDING. VYXEOS IS A LIPOSOMAL FORMULATION; DO NOT SUBSTITUTE FOR OTHER DAUNORUBICIN OR CYTARABINE PRODUCTS.
Cardiotoxicity (cumulative dose-dependent, monitor LVEF), myelosuppression (neutropenia, thrombocytopenia), infusion reactions (premedicate), hand-foot syndrome (palmar-plantar erythrodysesthesia), secondary malignancies, extravasation necrosis, hepatic impairment (dose adjustment), immunosuppression, embryo-fetal toxicity.
Cardiotoxicity: Left ventricular dysfunction, especially with cumulative doses; monitor cardiac function.,Myelosuppression: Severe, can lead to fatal infections or bleeding.,Hemorrhage: Fatal hemorrhages reported.,Tumor lysis syndrome: Risk due to rapid lysis.,Hepatotoxicity: Elevations in bilirubin and transaminases.,Embryo-fetal toxicity: Can cause fetal harm; advise effective contraception.
Absolute: history of hypersensitivity to doxorubicin or other anthracyclines. Relative: severe hepatic impairment, severe myelosuppression, pre-existing cardiomyopathy, prior treatment with maximum cumulative doses of anthracyclines (e.g., doxorubicin >550 mg/m², liposomal doxorubicin >900 mg/m²).
Hypersensitivity to daunorubicin, cytarabine, or any component of the formulation.,History of serious hypersensitivity reactions to any conventional daunorubicin or cytarabine product.
No specific food interactions reported. Avoid grapefruit juice per general chemotherapy precautions. Maintain adequate oral hygiene; avoid spicy or acidic foods during mucositis.
No specific food interactions reported. Avoid grapefruit and grapefruit juice due to potential CYP3A4 interaction with other components, although data are limited. Maintain adequate hydration to prevent tumor lysis syndrome.
Doxorubicin hydrochloride liposome injection (DOXIL) is classified as Pregnancy Category D. There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans. Potential benefits may warrant use of the drug in pregnant women despite potential risks. First trimester: High risk of teratogenicity including major malformations (e.g., cardiovascular, neural tube defects). Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and neonatal myelosuppression. Use only if clearly needed and no safer alternative.
VYXEOS (daunorubicin and cytarabine liposome) is contraindicated in pregnancy. It is embryotoxic and fetotoxic in animals. First trimester: high risk of major malformations (neural tube, cardiac). Second/third trimester: risk of fetal growth restriction, preterm birth, and neonatal myelosuppression. Use effective contraception.
Doxorubicin is excreted in human milk. The milk-to-plasma (M/P) ratio for doxorubicin is approximately 0.5 to 2.0 based on limited data. Because of the potential for serious adverse reactions in nursing infants from doxorubicin (e.g., myelosuppression, cardiotoxicity), discontinue breastfeeding during and for at least 3 months after the last dose of DOXIL.
Not recommended. It is unknown if excreted into human milk. M/P ratio not available. Advise to discontinue breastfeeding during treatment and for at least 1 month after last dose due to potential for serious adverse reactions in breastfed infants.
Pharmacokinetic data in pregnancy are limited; however, physiological changes (e.g., increased plasma volume, hepatic clearance) may alter doxorubicin exposure. No specific dose adjustment guidelines exist. Use the standard dose based on body surface area (BSA) while closely monitoring for toxicity. Consider dose reduction if severe myelosuppression or hepatic impairment occurs. Avoid use in the first trimester if possible.
No established dosing guidelines in pregnancy. Avoid use; if therapy is necessary, dose adjustments based on pharmacokinetic changes are not defined. Use only if potential benefit justifies risk to fetus.
Monitor for infusion reactions; premedicate with dexamethasone and antihistamines. Palmar-plantar erythrodysesthesia (hand-foot syndrome) may require dose delay/reduction. Cumulative dose >550 mg/m² increases cardiotoxicity risk. Do not substitute with non-liposomal doxorubicin.
VYXEOS is a liposomal encapsulation of daunorubicin and cytarabine in a fixed 1:5 molar ratio. It is indicated for adults with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). Do not substitute with other daunorubicin/cytarabine products due to different pharmacokinetics. Monitor for cardiotoxicity (echocardiogram prior to each cycle), myelosuppression, and hepatotoxicity. Premedicate for infusion reactions. Administer as a 90-minute IV infusion on days 1, 3, and 5; no dose adjustment for mild-moderate renal or hepatic impairment but avoid in severe impairment.
Report immediately any redness, swelling, or pain on palms or soles (hand-foot syndrome).,Avoid prolonged sun exposure and use sunscreen to prevent photosensitivity.,Notify your doctor if you experience chest pain, shortness of breath, or swelling (cardiotoxicity signs).,Take anti-nausea medications as prescribed; maintain adequate hydration.,Use effective contraception during treatment and for 6 months after.
VYXEOS is a combination chemotherapy used for certain types of acute myeloid leukemia.,It is given as an intravenous infusion over 90 minutes on days 1, 3, and 5 of each treatment cycle.,Common side effects include fever, infection, nausea, vomiting, diarrhea, constipation, mouth sores, fatigue, and bleeding or bruising.,You will have regular blood tests to monitor blood counts, heart function, and liver function.,Report any signs of infection (fever, chills), bleeding (unusual bruising, black stools), shortness of breath, or chest pain immediately.,Avoid pregnancy and breastfeeding while on this medication.,Do not take any other medications, including over-the-counter drugs or supplements, without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DOXIL (LIPOSOMAL) vs VYXEOS, answered by our medical review team.
DOXIL (LIPOSOMAL) is a Anthracycline Antineoplastic that works by Doxorubicin intercalates between DNA base pairs, inhibits topoisomerase II, and generates free radicals, leading to DNA damage and cell death. Liposomal encapsulation prolongs circulation time and alters biodistribution.. VYXEOS is a Liposomal Antineoplastic Combination that works by Daunorubicin and cytarabine are both antineoplastic agents. Daunorubicin intercalates with DNA, inhibits topoisomerase II, and generates free radicals leading to DNA damage and cell death. Cytarabine is a nucleoside analog that inhibits DNA polymerase by competing with cytidine triphosphate, incorporating into DNA and RNA, and causing chain termination.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DOXIL (LIPOSOMAL) and VYXEOS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DOXIL (LIPOSOMAL) is: Doxorubicin HCl liposome injection 20 mg/m2 intravenously over 1 hour every 4 weeks.. The standard adult dose of VYXEOS is: Each unit contains 44 mg daunorubicin and 100 mg cytarabine. Adults: 1 unit/m² IV over 90 minutes on days 1, 3, and 5 for induction; up to 2 cycles. For consolidation: 1 unit/m² IV over 90 minutes on days 1 and 3; up to 2 cycles.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DOXIL (LIPOSOMAL) and VYXEOS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DOXIL (LIPOSOMAL) is classified as Category C. Doxorubicin hydrochloride liposome injection (DOXIL) is classified as Pregnancy Category D. There is positive evidence of human fetal risk based on adverse reaction data from inves. VYXEOS is classified as Category C. VYXEOS (daunorubicin and cytarabine liposome) is contraindicated in pregnancy. It is embryotoxic and fetotoxic in animals. First trimester: high risk of major malformations (neural. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.